We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Philips (PHG) Q4 Earnings Beat Estimates, Revenues Fall Y/Y
Read MoreHide Full Article
Koninklijke Philips N.V. (PHG - Free Report) reported fourth-quarter 2023 adjusted earnings of 44 cents per share, outpacing the Zacks Consensus Estimate by 7.3%.
Revenues of $5.45 billion missed the consensus mark by 0.4%.
In domestic currency, sales decreased 7% on a year-over-year basis to €5.06 billion.
Comparable sales (including adjustments for consolidation charges & currency effects) declined 1% year over year. The decline was attributed to provisions charged to sales of €174 million, mainly in connection with the Respironics consent decree, excluding which comparable sales increased 3% year over year.
This growth was primarily attributed to the robust performance of the Diagnosis & Treatment and Personal Health segments.
Comparable sales in the Diagnosis & Treatment and Personal Health businesses recorded mid-single-digit and high-single-digit growth year over year, respectively.
However, comparable sales in the Connected Care business witnessed a low double-digit decline on a year-over-year basis.
Further, Philips’ comparable order intake declined 3% year over year in the reported quarter, primarily due to tough comparison.
Sales improved 7% on a comparable basis in growth geographies. Sales in mature geographies were down 4% year over year on a comparable basis.
Koninklijke Philips N.V. Price, Consensus and EPS Surprise
Diagnosis & Treatment revenues declined 2% from the year-ago quarter to €2.5 billion. Comparable sales jumped 5% year over year, driven by high-single-digit growth in Image-Guided Therapy.
Connected Care revenues decreased 17% year over year to €1.35 billion. Comparable sales fell 11%. Excluding provisions charged to sales related to Respironics consent decree, comparable sales remained flat with high single-digit growth in Enterprise Informatics.
Personal Health revenues rose 1% year over year to €1.07 billion. Comparable sales rose 7% year over year, owing to strength in Personal Care.
Other segment sales amounted to €143 million, down 26.3% on a year-over-year basis.
Operating Details
Gross margin contracted 550 basis points (bps) on a year-over-year basis to 35.5% in the reported quarter.
General & administrative expenses, as a percentage of sales, were 2.8%, which contracted 80 bps on a year-over-year basis. Moreover, selling expenses expanded 40 bps to 24.1%. Research & development expenses dipped 30 bps to 8.9%.
Restructuring, acquisition-related and other charges came in at €547 million compared with €350 million a year ago.
Operating model productivity, procurement and other productivity programs delivered savings of €149 million, €64 million and €58 million, respectively. This resulted in total savings of €271 million.
Phillips’ adjusted earnings before interest, taxes and amortization (EBITA) — the company’s preferred measure of operational performance — rose 0.3% year over year to €653 million. EBITA margin expanded 90 bps on a year-over-year basis to 12.9% in the reported quarter.
Diagnosis & Treatment’s adjusted EBITA margin contracted 180 bps on a year-over-year basis to 10.4%, primarily due to an unfavorable mix and phasing of production and costs.
Connected Care’s adjusted EBITA margin was 13.3% in the reported quarter, which expanded 170 bps on a year-over-year basis.
Personal Health’s adjusted EBITA margin expanded 290 bps on a year-over-year basis to 19.9%.
Balance Sheet
As of Dec 31, 2023, Philips’ cash and cash equivalents were €1.87 billion compared with €1.15 billion as of Sep 30, 2023. Total debt was €7.7 billion compared with €8.16 billion as of Sep 30, 2023.
Operating cash flow was €1.3 billion against the year-ago quarter’s operating cash flow of €540 million.
Free cash flow was €1.13 million against the year-ago quarter’s free cash flow of €303 million.
2024 Guidance
Philips expects to deliver 3-5% of comparable sales growth.
Further, adjusted EBITA margin is expected in the band of 11-11.5%.
Philips expects free cash flow to be between €800 million and €1 billion.
Zacks Rank & Stocks to Consider
Currently, Philips carries a Zacks Rank #4 (Sell).
Image: Bigstock
Philips (PHG) Q4 Earnings Beat Estimates, Revenues Fall Y/Y
Koninklijke Philips N.V. (PHG - Free Report) reported fourth-quarter 2023 adjusted earnings of 44 cents per share, outpacing the Zacks Consensus Estimate by 7.3%.
Revenues of $5.45 billion missed the consensus mark by 0.4%.
In domestic currency, sales decreased 7% on a year-over-year basis to €5.06 billion.
Comparable sales (including adjustments for consolidation charges & currency effects) declined 1% year over year. The decline was attributed to provisions charged to sales of €174 million, mainly in connection with the Respironics consent decree, excluding which comparable sales increased 3% year over year.
This growth was primarily attributed to the robust performance of the Diagnosis & Treatment and Personal Health segments.
Comparable sales in the Diagnosis & Treatment and Personal Health businesses recorded mid-single-digit and high-single-digit growth year over year, respectively.
However, comparable sales in the Connected Care business witnessed a low double-digit decline on a year-over-year basis.
Further, Philips’ comparable order intake declined 3% year over year in the reported quarter, primarily due to tough comparison.
Sales improved 7% on a comparable basis in growth geographies. Sales in mature geographies were down 4% year over year on a comparable basis.
Koninklijke Philips N.V. Price, Consensus and EPS Surprise
Koninklijke Philips N.V. price-consensus-eps-surprise-chart | Koninklijke Philips N.V. Quote
Segmental Update
Diagnosis & Treatment revenues declined 2% from the year-ago quarter to €2.5 billion. Comparable sales jumped 5% year over year, driven by high-single-digit growth in Image-Guided Therapy.
Connected Care revenues decreased 17% year over year to €1.35 billion. Comparable sales fell 11%. Excluding provisions charged to sales related to Respironics consent decree, comparable sales remained flat with high single-digit growth in Enterprise Informatics.
Personal Health revenues rose 1% year over year to €1.07 billion. Comparable sales rose 7% year over year, owing to strength in Personal Care.
Other segment sales amounted to €143 million, down 26.3% on a year-over-year basis.
Operating Details
Gross margin contracted 550 basis points (bps) on a year-over-year basis to 35.5% in the reported quarter.
General & administrative expenses, as a percentage of sales, were 2.8%, which contracted 80 bps on a year-over-year basis. Moreover, selling expenses expanded 40 bps to 24.1%. Research & development expenses dipped 30 bps to 8.9%.
Restructuring, acquisition-related and other charges came in at €547 million compared with €350 million a year ago.
Operating model productivity, procurement and other productivity programs delivered savings of €149 million, €64 million and €58 million, respectively. This resulted in total savings of €271 million.
Phillips’ adjusted earnings before interest, taxes and amortization (EBITA) — the company’s preferred measure of operational performance — rose 0.3% year over year to €653 million. EBITA margin expanded 90 bps on a year-over-year basis to 12.9% in the reported quarter.
Diagnosis & Treatment’s adjusted EBITA margin contracted 180 bps on a year-over-year basis to 10.4%, primarily due to an unfavorable mix and phasing of production and costs.
Connected Care’s adjusted EBITA margin was 13.3% in the reported quarter, which expanded 170 bps on a year-over-year basis.
Personal Health’s adjusted EBITA margin expanded 290 bps on a year-over-year basis to 19.9%.
Balance Sheet
As of Dec 31, 2023, Philips’ cash and cash equivalents were €1.87 billion compared with €1.15 billion as of Sep 30, 2023. Total debt was €7.7 billion compared with €8.16 billion as of Sep 30, 2023.
Operating cash flow was €1.3 billion against the year-ago quarter’s operating cash flow of €540 million.
Free cash flow was €1.13 million against the year-ago quarter’s free cash flow of €303 million.
2024 Guidance
Philips expects to deliver 3-5% of comparable sales growth.
Further, adjusted EBITA margin is expected in the band of 11-11.5%.
Philips expects free cash flow to be between €800 million and €1 billion.
Zacks Rank & Stocks to Consider
Currently, Philips carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader medical market sector are DaVita (DVA - Free Report) , Amedisys (AMED - Free Report) and Encompass Health (EHC - Free Report) . While DaVita sports a Zacks Rank #1 (Strong Buy) at present, Amedisys and Encompass Health carry a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here.
DaVita shares have gained 31.5% in the past year. The long-term earnings growth rate for DVA is currently projected at 17.26%
Amedisys shares have lost 1.5% in the past year. AMED’s long-term earnings growth rate is currently projected at 9.58%.
Encompass Health shares have lost 14.7% in the past year. The long-term earnings growth rate for EHC is currently projected at 13.51%